C reactive protein utilisation, a biomarker for early COVID-19 treatment, improves lenzilumab efficacy: results from the randomised phase 3 ‘LIVE-AIR’ trial

OBJECTIVE: COVID-19 severity is correlated with granulocyte macrophage colony-stimulating factor (GM-CSF) and C reactive protein (CRP) levels. In the phase three LIVE-AIR trial, lenzilumab an anti-GM-CSF monoclonal antibody, improved the likelihood of survival without ventilation (SWOV) in COVID-19,...

Descripción completa

Detalles Bibliográficos
Autores principales: Temesgen, Zelalem, Kelley, Colleen F, Cerasoli, Frank, Kilcoyne, Adrian, Chappell, Dale, Durrant, Cameron, Ahmed, Omar, Chappell, Gabrielle, Catterson, Victoria, Polk, Christopher, Badley, Andrew, Marconi, Vincent C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Respiratory Infection
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10314034/
https://www.ncbi.nlm.nih.gov/pubmed/35793833
http://dx.doi.org/10.1136/thoraxjnl-2022-218744

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10314034/
https://www.ncbi.nlm.nih.gov/pubmed/35793833
http://dx.doi.org/10.1136/thoraxjnl-2022-218744

Ejemplares similares